The Evolving Threat of ESBL, AmpC, and KPC -lactamases - SWACM
The Evolving Threat of ESBL, AmpC, and KPC -lactamases - SWACM The Evolving Threat of ESBL, AmpC, and KPC -lactamases - SWACM
Evolution of ESBLs TEM-3, 4 ......…………....178 SHV-2, 3 ...………….......134 CTX-M-1, 2……………….113 OXA-2, 10……………......161
Failures of Cephalosporin Therapy in Serious Infections with ESBL-positive K. pneumoniae Isolates reported susceptible to the cephalosporins Cephalosporin failed in 15/28 (54%) patients 4 of 5 were treated with cefepime! D. Paterson et al JCM (2001) 39: 2206-2212
- Page 1: The Evolving Threat of ESBL, AmpC,
- Page 4 and 5: Normal Gram-negative
- Page 6 and 7: ß-lactamases O CH 2 C NH O N S CH
- Page 8 and 9: Old Plasmid-Encoded ß-lactamases T
- Page 10 and 11: 3 rd Generation Cephalosporins Cefo
- Page 14 and 15: ESBL-producing Organisms Most Commo
- Page 16 and 17: CLSI 2010 (M100-S20) • If laborat
- Page 18 and 19: 2010 Breakpoints: Are they sufficie
- Page 20: Inoculum Effect: In Vitro Artifact?
- Page 23 and 24: -lactams Still Active Carbapenems C
- Page 25 and 26: AmpC-mediated Resistance Resistant
- Page 27 and 28: Plasmid-mediated AmpCs • Klebsiel
- Page 29 and 30: Clinical Significance of AmpC for K
- Page 31 and 32: Klebsiella pneumoniae 225 Resistant
- Page 34 and 35: Carbapenemases Class A (KPC, GES, S
- Page 36 and 37: Miami KPC Outbreak • Admission fi
- Page 38 and 39: Which MIC do we use? Carbapenem MIC
- Page 41: Thanks for your attention!
Evolution <strong>of</strong> <strong>ESBL</strong>s<br />
TEM-3, 4 ......…………....178<br />
SHV-2, 3 ...………….......134<br />
CTX-M-1, 2……………….113<br />
OXA-2, 10……………......161
Change language